Predicting Efficacy of Adjuvant Tamoxifen for EarlyStage Breast Cancer
Predicting Efficacy of Adjuvant Tamoxifen for Early-Stage Breast Cancer
20:57 EDT 1 Apr 2019 |
NEJM
Neither a patient's CPY2D6 status nor endoxifen concentration affected relapse-free survival.
Original Article: Predicting Efficacy of Adjuvant Tamoxifen for Early-Stage Breast Cancer
More From BioPortfolio on "Predicting Efficacy of Adjuvant Tamoxifen for Early-Stage Breast Cancer"